These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27737601)

  • 21. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues.
    Wolfe F; Michaud K; Dewitt EM
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii13-ii17. PubMed ID: 15479864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 24. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.
    Kalden JR
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S34-40. PubMed ID: 12110156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proceedings of the XIIth International Symposium on Advances in Targeted Therapies. April 14-18, 2010.
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i1-122. PubMed ID: 21438187
    [No Abstract]   [Full Text] [Related]  

  • 27. Advances in use of immunomodulatory agents--a rheumatology perspective.
    Her M; Kavanaugh A
    Nat Rev Gastroenterol Hepatol; 2015 Jun; 12(6):363-8. PubMed ID: 25895821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risks associated with use of TNF inhibitors in children with rheumatic diseases.
    Marino A; Giani T; Cimaz R
    Expert Rev Clin Immunol; 2019 Feb; 15(2):189-198. PubMed ID: 30451548
    [No Abstract]   [Full Text] [Related]  

  • 29. [Biological treatment of rhematoid diseases].
    Pavelka K
    Vnitr Lek; 2006 Jun; 52(6):561-2. PubMed ID: 16871758
    [No Abstract]   [Full Text] [Related]  

  • 30. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
    Yelin E; Katz P
    Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
    [No Abstract]   [Full Text] [Related]  

  • 31. Patient-tailored therapy in rheumatoid arthritis: an editorial review.
    Scherer HU; Dörner T; Burmester GR
    Curr Opin Rheumatol; 2010 May; 22(3):237-45. PubMed ID: 20177384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biological treatment of rheumatic diseases].
    Procházková L; Böhmová J; Soucek M
    Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pregnancy in rheumatic patients treated with biologic drugs].
    Sentić M; Baresić M; Anić B; Bosnić D; Cerovec M; Mayer M; Smiljanić L; Cikes N
    Lijec Vjesn; 2010; 132(9-10):317-8. PubMed ID: 21261033
    [No Abstract]   [Full Text] [Related]  

  • 34. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-adalimumab antibodies in paediatric rheumatology patients: a pilot experience.
    Murias S; Alcobendas R; Pascual-Salcedo D; Remesal A; Peralta J; Merino R
    Rheumatology (Oxford); 2014 Nov; 53(11):2124-6. PubMed ID: 25102859
    [No Abstract]   [Full Text] [Related]  

  • 36. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
    Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
    Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
    [No Abstract]   [Full Text] [Related]  

  • 37. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are biological drugs safe in pregnancy?
    Calligaro A; Hoxha A; Ruffatti A; Punzi L
    Reumatismo; 2015 Mar; 66(4):304-17. PubMed ID: 25829190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine history knowledge of subcutaneous anti-TNF receiving rheumatology patients.
    Nolan TJ; O'Connor MB; Bond U; Swan J; Phelan MJ
    Rheumatol Int; 2013 Jul; 33(7):1907-8. PubMed ID: 22441967
    [No Abstract]   [Full Text] [Related]  

  • 40. Rheumatoid vasculitis treated with infliximab.
    van der Bijl AE; Allaart CF; Van Vugt J; Van Duinen S; Breedveld FC
    J Rheumatol; 2005 Aug; 32(8):1607-9. PubMed ID: 16078342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.